

13. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2024;105(4S):S117–S314.
14. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2026 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Public Review Draft, March 2026. [Internet]. Available from: <<https://kdigo.org>>.
15. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. *Eur Heart J.* 2023;44(39):4043–4140.
16. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). *N Engl J Med.* 2023;389(12):1069–1084.
17. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes (STEP-HFpEF DM). *N Engl J Med.* 2024;390(15):1394–1407.
18. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). *N Engl J Med.* 2025;392(5):427–437.
19. Shokravi A, Seth J, Mancini GBJ. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. *Cardiovasc Diabetol.* 2025;24(1):370.
20. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2026; doi: 10.1016/j.jacc.2025. 11. 016.
21. Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J.* 2025;46(42):4359–4378.
22. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). *N Engl J Med.* 2015;372(25):2387–2397.
23. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with ASCVD (RACING). *Lancet.* 2022;400(10349):380–390.

24. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). *N Engl J Med.* 2017;376(18):1713–1722.
25. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). *N Engl J Med.* 2018;379(22):2097–2107.
26. O'Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease (FOURIER-OLE). *Circulation.* 2022;146(15):1109–1119.
27. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). *N Engl J Med.* 2020;382(16):1507–1519.
28. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). *N Engl J Med.* 2023;388(15):1353–1364.
29. Khine MT, De P, Frankel AH, et al. Consensus Statement: Finerenone in the Management of Diabetes Kidney Disease (ABCD/UKKA). *Br J Diabetes.* 2024;24(2):1–14.
30. Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnett C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. *Circulation.* 2024;149(6):450–462.
31. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2023;44(37):3627–3639.
32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet.* 1998;352(9131):854–865.
33. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet.* 2005;366(9493):1279–1289.
34. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (IRIS). *N Engl J Med.* 2016;374(14):1321–1331.

ON-LINE KURZ

Závratě z pohledu ORL lékaře

ODBORNÝ PROGRAM

-  **Závratě z pohledu ORL lékaře**
MUDr. Vladimír Koucký, Ph.D.
-  **Algoritmy diagnostiky a léčby závrativých stavů**
doc. MUDr. Jaroslav Jeřábek, CSc.
-  **Poruchy stability u pacientů s benigním paroxysmálním polohovým vertigem**
doc. PhDr. Ondřej Čákrť, Ph.D., doc. MUDr. Jaroslav Jeřábek, CSc.
-  **Nevestibulárne závraty** — prof. MUDr. Egon Kurča, Ph.D.

ODBORNÝ GARANT:

MUDr. Pavel Rutar

Interní oddělení, Nemocnice Na Homolce, Praha

POŘADATEL:

Společnost SOLEN, s. r. o., ve spolupráci
s Interním oddělením, Nemocnice Na Homolce

**POČET
KREDITŮ 2**

**Registrace
ZDARMA**

TERMÍN
prosinec 2025
až listopad 2026
dostupný na
online.solen.cz

ZLATÝ
PARTNER

